What intervention is crucial for a neonate born to a mother who was on anticoagulants?

Monitoring for signs of bleeding and potential interventions if necessary is crucial for a neonate born to a mother who was on anticoagulants due to the risk of bleeding complications. Anticoagulants can cross the placenta and affect the newborn, potentially leading to an increased risk of hemorrhage. After birth, the neonate may have low levels of vitamin K-dependent clotting factors or may experience coagulopathy.

Therefore, careful observation for any signs of bleeding, such as bruising, petechiae, or unexpected blood loss, is essential. If any signs of bleeding are observed, timely interventions, such as administering vitamin K to promote clotting, might be necessary to prevent serious complications. This vigilant monitoring ensures the well-being of the newborn and helps in managing any potential risks associated with the mother’s anticoagulant therapy.

Other options, such as providing immunization immediately, initiating breastfeeding, or discharging the baby early, do not address the immediate clinical risks associated with potential bleeding in neonates exposed to anticoagulants. While these actions may be important in a general setting, they do not prioritize the critical need for evaluating the newborn's safety regarding bleeding risks.